Her chief research interest is the development of viral vectored vaccines that work by inducing strong and protective T and B cell responses. She has led work on influenza vaccine development and on vaccines for many different emerging pathogens, including Nipah virus, MERS, Lassa virus and CCHF virus. Professor Gilbert’s work also focuses on the rapid transfer of vaccines into GMP manufacturing and first in human trials.

She was the Oxford Project Leader for ChAdOx1 nCoV-19, known as the Oxford-AstraZeneca vaccine against COVID 19.